EUVIMEDEUVIMED entdecken
Crossref

Effects of MYC Inhibitors on the Growth of Acute Leukaemia Cells

Kotomi Noguchi, Mai Itoh, Chisuzu Ito, Shuji Tohda

Anticancer Research · 2023

DOI: 10.21873/anticanres.16473 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2023. Verfasst von Kotomi Noguchi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Proto-Oncogene Proteins c-myc. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: MYC proto-oncogene bHLH transcription factor (MYC) proteins function as transcription factors by binding to MYC-associated factor X (MAX) proteins and are involved in various cancer growth, including leukaemia. This study aimed to examine the effects of synthetic MYC inhibitors, which block the MYC-MAX complex formation, in in vitro human acute leukaemia cell lines. MATERIALS AND METHODS: Four cell lines, OCI/AML2 derived from acute myeloid leukaemia, NALM-6 from B-lymphoblastic leukaemia, and KOPT-K1 and Jurkat from notch receptor 1 (NOTCH1)-mutated T-lymphoblastic leukaemia (T-ALL), were treated with the small-molecule MYC inhibitors 10058-F4 and MYCi975. The expression of cell proliferation and signalling proteins was studied. RESULTS: These inhibitors suppressed the growth of leukaemia cell lines. Treatment with the two inhibitors down-regulated the protein expression of c-MYC, MAX, and activating enhancer-binding protein 4 (AP4) in all cell lines. Up-regulation of p27 and p21 was observed only in 10058-F4-treated OCI/AML2 cells and MYCi975-treated KOPT-K1 cells. These two inhibitors down-regulated the expression of NOTCH1, cleaved NOTCH1, and hes family bHLH transcription factor 1 (HES1) in both T-ALL cell lines. CONCLUSION: MYC inhibitors appear to be novel molecular-targeted drugs against acute leukaemia, including NOTCH1-mutated T-ALL. However, it is necessary to elucidate the precise molecular mechanisms of these effects before clinical use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaProto-Oncogene Proteins c-mycHumansAcute DiseaseCell Line, TumorCell ProliferationReceptor, Notch1

Stichwörter der Autor:innen

MYCMYC inhibitorMYC–MAX complexleukaemia

Substanzen

Proto-Oncogene Proteins c-mycReceptor, Notch1

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
  • Department of Laboratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan tohda.mlab@tmd.ac.jp.

Zitieren

APA

Noguchi, K., Itoh, M., Ito, C., & Tohda, S. (2023). Effects of MYC Inhibitors on the Growth of Acute Leukaemia Cells. Anticancer Research. https://doi.org/10.21873/anticanres.16473

Vancouver

Noguchi K, Itoh M, Ito C, Tohda S. Effects of MYC Inhibitors on the Growth of Acute Leukaemia Cells. Anticancer Research. 2023. doi:10.21873/anticanres.16473

BibTeX
@article{Noguchi2023,
  author = {Noguchi, Kotomi and Itoh, Mai and Ito, Chisuzu and Tohda, Shuji},
  title = {Effects of MYC Inhibitors on the Growth of Acute Leukaemia Cells},
  journal = {Anticancer Research},
  year = {2023},
  doi = {10.21873/anticanres.16473}
}
Kostenlos starten →